TY - JOUR
T1 - Effective Use of Percutaneous Stellate Ganglion Blockade in Patients with Electrical Storm
AU - Tian, Ying
AU - Wittwer, Erica D.
AU - Kapa, Suraj
AU - McLeod, Christopher J.
AU - Xiao, Peilin
AU - Noseworthy, Peter A.
AU - Mulpuru, Siva K.
AU - Deshmukh, Abhishek J.
AU - Lee, Hon Chi
AU - Ackerman, Michael J.
AU - Asirvatham, Samuel J.
AU - Munger, Thomas M.
AU - Liu, Xing Peng
AU - Friedman, Paul A.
AU - Cha, Yong Mei
N1 - Publisher Copyright:
© 2019 American Heart Association, Inc.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Background: Percutaneous stellate ganglion blockade (SGB) has been used for drug-refractory electrical storm due to ventricular arrhythmia (VA); however, the effects and long-term outcomes have not been well studied. Methods: This study included 30 consecutive patients who had drug-refractory electrical storm and underwent percutaneous SGB between October 1, 2013, and March 31, 2018. Bupivacaine, alone or combined with lidocaine, was injected into the neck with good local anesthetic spread in the vicinity of the left stellate ganglion (n=15) or both stellate ganglia (n=15). Data were collected for patient clinical characteristics, immediate and long-term outcomes, and procedure-related complications. Results: Clinical characteristics included age, 58±14 years; men, 73.3%; and left ventricular ejection fraction, 34±16%. At 24 hours, 60% of patients were free of VA. Patients whose VA was controlled had a lower hospital mortality rate than patients whose VA continued (5.6% versus 50.0%; P=0.009). Implantable cardioverter-defibrillator interrogation showed a significant 92% reduction in VA episodes from 26±41 to 2±4 in the 72 hours after SGB (P<0.001). Patients who died during the same hospitalization (n=7) were more likely to have ischemic cardiomyopathy (100% versus 43.5%; P=0.03) and recurrent VA within 24 hours (85.7% versus 26.1%; P=0.009). There were no procedure-related major complications. Conclusions: SGB effectively attenuated electrical storm in more than half of patients without procedure-related complications. Percutaneous SGB may be considered for stabilizing ventricular rhythm in patients for whom other therapies have failed.
AB - Background: Percutaneous stellate ganglion blockade (SGB) has been used for drug-refractory electrical storm due to ventricular arrhythmia (VA); however, the effects and long-term outcomes have not been well studied. Methods: This study included 30 consecutive patients who had drug-refractory electrical storm and underwent percutaneous SGB between October 1, 2013, and March 31, 2018. Bupivacaine, alone or combined with lidocaine, was injected into the neck with good local anesthetic spread in the vicinity of the left stellate ganglion (n=15) or both stellate ganglia (n=15). Data were collected for patient clinical characteristics, immediate and long-term outcomes, and procedure-related complications. Results: Clinical characteristics included age, 58±14 years; men, 73.3%; and left ventricular ejection fraction, 34±16%. At 24 hours, 60% of patients were free of VA. Patients whose VA was controlled had a lower hospital mortality rate than patients whose VA continued (5.6% versus 50.0%; P=0.009). Implantable cardioverter-defibrillator interrogation showed a significant 92% reduction in VA episodes from 26±41 to 2±4 in the 72 hours after SGB (P<0.001). Patients who died during the same hospitalization (n=7) were more likely to have ischemic cardiomyopathy (100% versus 43.5%; P=0.03) and recurrent VA within 24 hours (85.7% versus 26.1%; P=0.009). There were no procedure-related major complications. Conclusions: SGB effectively attenuated electrical storm in more than half of patients without procedure-related complications. Percutaneous SGB may be considered for stabilizing ventricular rhythm in patients for whom other therapies have failed.
KW - hospital mortality
KW - hospitalization
KW - stellate ganglion block
KW - sympathetic nervous system
KW - ventricular arrhythmia
UR - http://www.scopus.com/inward/record.url?scp=85072143267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072143267&partnerID=8YFLogxK
U2 - 10.1161/CIRCEP.118.007118
DO - 10.1161/CIRCEP.118.007118
M3 - Article
C2 - 31514529
AN - SCOPUS:85072143267
SN - 1941-3149
VL - 12
JO - Circulation: Arrhythmia and Electrophysiology
JF - Circulation: Arrhythmia and Electrophysiology
IS - 9
ER -